Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 4/20 | 0.57 |
| ▸ | CDK2 | P24941 | 4/20 | 0.57 |
| ▸ | CDK1 | P06493 | 3/20 | 0.57 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.45 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3305032 | 0.83 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL608687 | 0.83 | CYP3A4 (0.68) | CYP3A4ADORA2AADORA1CYP2D6FAP | |
| SCHEMBL3860366 | 0.82 | CCNE1 (0.51) | CCNE1CDK2CDK1CCNB1SLC29A1 | |
| SCHEMBL8620522 | 0.82 | CCNE1 (0.51) | CCNE1CDK2CDK1CCNB1SLC29A1 | |
| SCHEMBL465830 | 0.82 | CCNE1 (0.51) | CCNE1CDK2CDK1CCNB1CYP3A4 | |
| SCHEMBL4312545 | 0.82 | CYP3A4 (0.73) | CCNE1CDK2CDK1CCNB1CYP3A4 | |
| SCHEMBL30515122 | 0.82 | CYP3A4 (0.73) | CCNE1CDK2CDK1CCNB1CYP3A4 | |
| SCHEMBL1032335 | 0.82 | CYP3A4 (0.73) | CCNE1CDK2CDK1CCNB1CYP3A4 | |
| SCHEMBL173030 | 0.82 | CYP3A4 (0.73) | CCNE1CDK2CDK1CCNB1CYP3A4 | |
| Water SCHEMBL28104578 | 0.82 | CYP3A4 (0.67) | CYP3A4ADORA2AADORA1CYP2D6FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6093816-A | Cationic lipids | ISIS PHARMACEUTICALS, INC. (US) | 2000-07-25 | — | — | US | claimed |
| EP-1753762-B1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS INC (US) | 2014-03-19 | — | — | EP | disclosed |
| EP-2707004-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FELINE RETROVIRAL INFECTIONS | Okapi Sciences NV (BE) | 2014-03-19 | — | — | EP | disclosed |
| US-20140073607-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FELINE RETROVIRAL INFECTIONS | OKAPI SCIENCES NV (BE) | 2014-03-13 | — | — | US | disclosed |
| WO-2012152317-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FELINE RETROVIRAL INFECTIONS | OKAPI SCIENCES NV (BE) | 2012-11-15 | — | — | WO | disclosed |
| US-7582758-B2 | producing cyclic phosphonic acid diesters prodrugs, used to improve the oral bioavailability; by reacting a chiral 1,3-diol and an activated phosphonic acid in the presence of a Lewis acid; Adefovir drug target delivery to liver | METABASIS THERAPEUTICS, INC. (US) | 2009-09-01 | — | — | US | disclosed |
| EP-1753762-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | Metabasis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | disclosed |
| WO-2005123729-A1 | LEWIS ACID MEDIATED SYNTHESIS OF CYCLIC ESTERS | METABASIS THERAPEUTICS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2005-12-22 | — | — | US | disclosed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | disclosed |
| WO-2004076687-A1 | METHOD FOR DETERMINING ANTIVIRAL ACTIVITY OF AHPS RELATED COMPOUNDS | UNIVERSITEIT UTRECHT HOLDING B.V. (NL) | 2004-09-10 | — | — | WO | disclosed |
| EP-1452605-A1 | Method for determining antiviral activity | Universiteit Utrecht Holding B.V. (NL) | 2004-09-01 | — | — | EP | disclosed |
| US-5686629-A | CHEMICAL INTERMEDIATES | GILEAD SCIENCES, INC. (US) | 1997-11-11 | — | — | US | disclosed |
| US-5514798-A | REACTION OF CYCLIC CARBONATE WITH PURINE OR PYRIMIDINE BASE IN SOLVENT AND CRYSTALLIZATION | GILEAD SCIENCES, INC. (US) | 1996-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282782-A1 | Lewis acid mediated synthesis of cyclic esters | PHOSPHO1, LPAR1, LPAR2 | CCNE1 988/4885CDK2 467/4885CDK1 759/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | CCNE1 2846/4885CDK2 449/4885CDK1 2011/4885 |
| US-20140073607-A1 | COMPOUNDS FOR USE IN THE TREATMENT OF FELINE RETROVIRAL INFECTIONS | PIGO, CAT, FLI1 | CCNE1 1921/4885CDK2 963/4885CDK1 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.